AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLOV
  4. [Form 4] Clover Health Investments, Corp Insider Trading Activity

[Form 4] Clover Health Investments, Corp Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Vivek Garipalli, a director and 10% owner of Clover Health Investments (CLOV), reported purchases of Class A common stock on 08/07/2025 and 08/08/2025. He acquired 415,000 shares on 08/07/2025 at a weighted average price of $2.24 and 31,980 shares on 08/08/2025 at a weighted average price of $2.17, bringing his reported direct ownership to 1,856,247 Class A shares.

Table II discloses substantial Class B common stock that converts one-for-one into Class A: 6,904,343 Class A-equivalent shares held directly, plus 11,500,000 and 72,084,543 Class A-equivalent shares held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC, respectively. The filing states Garipalli serves as sole manager of those LLCs.

Vivek Garipalli, amministratore e proprietario del 10% di Clover Health Investments (CLOV), ha riportato acquisti di azioni ordinarie di Classe A il 08/07/2025 e il 08/08/2025. Ha acquisito 415,000 azioni il 08/07/2025 a un prezzo medio ponderato di $2.24 e 31,980 azioni il 08/08/2025 a un prezzo medio ponderato di $2.17, portando la sua partecipazione diretta dichiarata a 1,856,247 azioni di Classe A.

La Tabella II segnala consistenti azioni ordinarie di Classe B convertibili uno a uno in azioni di Classe A: 6,904,343 azioni equivalenti Classe A detenute direttamente, oltre a 11,500,000 e 72,084,543 azioni equivalenti Classe A detenute indirettamente da Caesar Clover, LLC e NJ Healthcare Investments, LLC, rispettivamente. Il deposito indica che Garipalli svolge la funzione di manager unico di tali LLC.

Vivek Garipalli, director y propietario del 10% de Clover Health Investments (CLOV), inform贸 compras de acciones ordinarias Clase A el 08/07/2025 y el 08/08/2025. Adquiri贸 415,000 acciones el 08/07/2025 a un precio promedio ponderado de $2.24 y 31,980 acciones el 08/08/2025 a un precio promedio ponderado de $2.17, elevando su propiedad directa informada a 1,856,247 acciones Clase A.

La Tabla II revela una cantidad sustancial de acciones ordinarias Clase B que se convierten una a una en Clase A: 6,904,343 acciones equivalentes Clase A en propiedad directa, adem谩s de 11,500,000 y 72,084,543 acciones equivalentes Clase A en propiedad indirecta por Caesar Clover, LLC y NJ Healthcare Investments, LLC, respectivamente. La presentaci贸n indica que Garipalli act煤a como administrador 煤nico de esas LLC.

Clover Health Investments (CLOV)鞚� 鞚挫偓鞚挫瀽 10% 歆�攵� 氤挫湢鞛愳澑 Vivek Garipalli電� 08/07/2025 氚� 08/08/2025鞐� 韥措灅鞀� A 氤错喌欤茧ゼ 毵れ垬頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 攴鸽姅 08/07/2025鞐� 臧�欷戫弶攴� 臧�瓴� $2.24鞐� 415,000欤茧ゼ, 08/08/2025鞐� 臧�欷戫弶攴� 臧�瓴� $2.17鞐� 31,980欤茧ゼ 旆摑頃橃棳 氤搓碃霅� 歆侅爲 氤挫湢霟夓潉 1,856,247 韥措灅鞀� A欤茧 電橂牳鞀惦媹雼�.

響� II電� 1雽�1搿� 韥措灅鞀� A搿� 鞝勴櫂霅橂姅 靸侂嫻頃� 韥措灅鞀� B 氤错喌欤茧ゼ 瓿奠嫓頃╇媹雼�: 歆侅爲 氤挫湢頃� 韥措灅鞀� A 頇橃偘 欤检嫕 6,904,343欤检檧 Caesar Clover, LLC 氚� NJ Healthcare Investments, LLC臧� 臧侁皝 臧勳爲 氤挫湢頃� 韥措灅鞀� A 頇橃偘 欤检嫕 11,500,000欤� 氚� 72,084,543欤缄皜 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� Garipalli電� 頃措嫻 LLC霌れ潣 雼弲 毵る媹鞝�搿� 霌膘灛霅橃柎 鞛堨姷雼堧嫟.

Vivek Garipalli, administrateur et d茅tenteur de 10% de Clover Health Investments (CLOV), a d茅clar茅 des achats d'actions ordinaires de classe A les 08/07/2025 et 08/08/2025. Il a acquis 415,000 actions le 08/07/2025 au prix moyen pond茅r茅 de $2.24 et 31,980 actions le 08/08/2025 au prix moyen pond茅r茅 de $2.17, portant sa participation directe d茅clar茅e 脿 1,856,247 actions de classe A.

Le tableau II r茅v猫le d'importantes actions ordinaires de classe B convertibles une pour une en classe A : 6,904,343 actions 茅quivalentes classe A d茅tenues directement, ainsi que 11,500,000 et 72,084,543 actions 茅quivalentes classe A d茅tenues indirectement par Caesar Clover, LLC et NJ Healthcare Investments, LLC, respectivement. Le d茅p么t indique que Garipalli est le gestionnaire unique de ces LLC.

Vivek Garipalli, Direktor und 10%-Eigent眉mer von Clover Health Investments (CLOV), meldete K盲ufe von Stammaktien der Klasse A am 08/07/2025 und 08/08/2025. Er erwarb am 08/07/2025 415,000 Aktien zu einem gewichteten Durchschnittspreis von $2.24 und am 08/08/2025 31,980 Aktien zu einem gewichteten Durchschnittspreis von $2.17, womit sein gemeldeter Direktbestand auf 1,856,247 Klasse-A-Aktien anstieg.

Tabelle II weist betr盲chtliche Klasse-B-Stammaktien aus, die eins zu eins in Klasse A umgewandelt werden: 6,904,343 Klasse-A-盲quivalente Aktien im Direktbesitz sowie 11,500,000 und 72,084,543 Klasse-A-盲quivalente Aktien, die jeweils indirekt von Caesar Clover, LLC bzw. NJ Healthcare Investments, LLC gehalten werden. Die Einreichung gibt an, dass Garipalli als alleiniger Manager dieser LLCs fungiert.

Positive
  • Insider purchases reported: 415,000 shares at a weighted average of $2.24 and 31,980 shares at $2.17, increasing direct ownership.
  • Direct ownership increased to 1,856,247 Class A shares following the transactions.
  • Large convertible Class B holdings are disclosed that convert one-for-one into Class A, providing economic alignment between share classes.
  • Reporting person is sole manager of Caesar Clover, LLC and NJ Healthcare Investments, LLC, clarifying the source of indirect holdings.
Negative
  • High concentration of convertible holdings: Indirect holdings of 11,500,000 and 72,084,543 Class A-equivalents may concentrate voting/economic power.
  • Incremental purchases are small relative to total convertible exposure, so the reported buys modestly change direct stake despite significant overall influence via Class B shares.

Insights

TL;DR: Material insider purchases alongside very large convertible Class B holdings, increasing direct stake modestly.

The Form 4 shows Garipalli purchased a total of 447,000 Class A shares across two days at weighted-average prices of $2.24 and $2.17, raising direct holdings to 1,856,247 shares. Equally important, Table II reports convertible Class B positions convertible one-for-one into Class A totaling tens of millions of shares (direct 6.9M; indirect 11.5M and 72.08M) held via two LLCs he manages. For investors, the filing confirms continued insider accumulation and concentrated voting/economic exposure via Class B instruments.

TL;DR: Insider buying is positive signal, but governance implications remain given concentrated Class B holdings held through managed LLCs.

The report documents incremental open-market purchases but also highlights that significant Class B convertible shares are held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC, entities for which Garipalli is sole manager. Those indirect holdings (11.5M and 72.08M Class A-equivalents) indicate concentrated control potential via convertible shares. The filing is informative about ownership structure but does not disclose any change in governance arrangements or conversion actions.

Vivek Garipalli, amministratore e proprietario del 10% di Clover Health Investments (CLOV), ha riportato acquisti di azioni ordinarie di Classe A il 08/07/2025 e il 08/08/2025. Ha acquisito 415,000 azioni il 08/07/2025 a un prezzo medio ponderato di $2.24 e 31,980 azioni il 08/08/2025 a un prezzo medio ponderato di $2.17, portando la sua partecipazione diretta dichiarata a 1,856,247 azioni di Classe A.

La Tabella II segnala consistenti azioni ordinarie di Classe B convertibili uno a uno in azioni di Classe A: 6,904,343 azioni equivalenti Classe A detenute direttamente, oltre a 11,500,000 e 72,084,543 azioni equivalenti Classe A detenute indirettamente da Caesar Clover, LLC e NJ Healthcare Investments, LLC, rispettivamente. Il deposito indica che Garipalli svolge la funzione di manager unico di tali LLC.

Vivek Garipalli, director y propietario del 10% de Clover Health Investments (CLOV), inform贸 compras de acciones ordinarias Clase A el 08/07/2025 y el 08/08/2025. Adquiri贸 415,000 acciones el 08/07/2025 a un precio promedio ponderado de $2.24 y 31,980 acciones el 08/08/2025 a un precio promedio ponderado de $2.17, elevando su propiedad directa informada a 1,856,247 acciones Clase A.

La Tabla II revela una cantidad sustancial de acciones ordinarias Clase B que se convierten una a una en Clase A: 6,904,343 acciones equivalentes Clase A en propiedad directa, adem谩s de 11,500,000 y 72,084,543 acciones equivalentes Clase A en propiedad indirecta por Caesar Clover, LLC y NJ Healthcare Investments, LLC, respectivamente. La presentaci贸n indica que Garipalli act煤a como administrador 煤nico de esas LLC.

Clover Health Investments (CLOV)鞚� 鞚挫偓鞚挫瀽 10% 歆�攵� 氤挫湢鞛愳澑 Vivek Garipalli電� 08/07/2025 氚� 08/08/2025鞐� 韥措灅鞀� A 氤错喌欤茧ゼ 毵れ垬頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. 攴鸽姅 08/07/2025鞐� 臧�欷戫弶攴� 臧�瓴� $2.24鞐� 415,000欤茧ゼ, 08/08/2025鞐� 臧�欷戫弶攴� 臧�瓴� $2.17鞐� 31,980欤茧ゼ 旆摑頃橃棳 氤搓碃霅� 歆侅爲 氤挫湢霟夓潉 1,856,247 韥措灅鞀� A欤茧 電橂牳鞀惦媹雼�.

響� II電� 1雽�1搿� 韥措灅鞀� A搿� 鞝勴櫂霅橂姅 靸侂嫻頃� 韥措灅鞀� B 氤错喌欤茧ゼ 瓿奠嫓頃╇媹雼�: 歆侅爲 氤挫湢頃� 韥措灅鞀� A 頇橃偘 欤检嫕 6,904,343欤检檧 Caesar Clover, LLC 氚� NJ Healthcare Investments, LLC臧� 臧侁皝 臧勳爲 氤挫湢頃� 韥措灅鞀� A 頇橃偘 欤检嫕 11,500,000欤� 氚� 72,084,543欤缄皜 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� Garipalli電� 頃措嫻 LLC霌れ潣 雼弲 毵る媹鞝�搿� 霌膘灛霅橃柎 鞛堨姷雼堧嫟.

Vivek Garipalli, administrateur et d茅tenteur de 10% de Clover Health Investments (CLOV), a d茅clar茅 des achats d'actions ordinaires de classe A les 08/07/2025 et 08/08/2025. Il a acquis 415,000 actions le 08/07/2025 au prix moyen pond茅r茅 de $2.24 et 31,980 actions le 08/08/2025 au prix moyen pond茅r茅 de $2.17, portant sa participation directe d茅clar茅e 脿 1,856,247 actions de classe A.

Le tableau II r茅v猫le d'importantes actions ordinaires de classe B convertibles une pour une en classe A : 6,904,343 actions 茅quivalentes classe A d茅tenues directement, ainsi que 11,500,000 et 72,084,543 actions 茅quivalentes classe A d茅tenues indirectement par Caesar Clover, LLC et NJ Healthcare Investments, LLC, respectivement. Le d茅p么t indique que Garipalli est le gestionnaire unique de ces LLC.

Vivek Garipalli, Direktor und 10%-Eigent眉mer von Clover Health Investments (CLOV), meldete K盲ufe von Stammaktien der Klasse A am 08/07/2025 und 08/08/2025. Er erwarb am 08/07/2025 415,000 Aktien zu einem gewichteten Durchschnittspreis von $2.24 und am 08/08/2025 31,980 Aktien zu einem gewichteten Durchschnittspreis von $2.17, womit sein gemeldeter Direktbestand auf 1,856,247 Klasse-A-Aktien anstieg.

Tabelle II weist betr盲chtliche Klasse-B-Stammaktien aus, die eins zu eins in Klasse A umgewandelt werden: 6,904,343 Klasse-A-盲quivalente Aktien im Direktbesitz sowie 11,500,000 und 72,084,543 Klasse-A-盲quivalente Aktien, die jeweils indirekt von Caesar Clover, LLC bzw. NJ Healthcare Investments, LLC gehalten werden. Die Einreichung gibt an, dass Garipalli als alleiniger Manager dieser LLCs fungiert.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Garipalli Vivek
(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE
(Street)
WILMINGTON DE 19801
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 08/07/2025 P 415,000 A $2.24(1) 1,824,267 D
Class A Common Stock 08/08/2025 P 31,980 A $2.17(2) 1,856,247 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Common Stock (3) (3) (3) Class A Common Stock 6,904,343 6,904,343 D
Class B Common Stock (3) (3) (3) Class A Common Stock 11,500,000 11,500,000 I Held by Ceasar Clover, LLC(4)
Class B Common Stock (3) (3) (3) Class A Common Stock 72,084,543 72,084,543 I Held by NJ Healthcare Investments, LLC(4)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.16 to $2.32, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 1 to this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.15 to $2.21, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 2 to this Form 4.
3. The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer.
4. The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC and Caesar Clover, LLC.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did Vivek Garipalli report on the CLOV Form 4?

He purchased 415,000 Class A shares on 08/07/2025 at a weighted average price of $2.24 and 31,980 Class A shares on 08/08/2025 at a weighted average price of $2.17.

How many Class A shares does Garipalli beneficially own after the reported transactions for CLOV?

The filing reports 1,856,247 Class A shares beneficially owned following the reported transactions.

What convertible or derivative holdings does Garipalli report for CLOV?

Table II discloses Class B common stock convertible one-for-one into Class A: 6,904,343 held directly, plus 11,500,000 and 72,084,543 held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC.

What is Garipalli's relationship to Clover Health Investments (CLOV)?

The form identifies Vivek Garipalli as a Director and a 10% owner of the issuer.

Who holds the indirect Class B positions reported in the Form 4?

The indirect holdings are held by Caesar Clover, LLC and NJ Healthcare Investments, LLC, and the filing states Garipalli serves as the sole manager of those LLCs.
Stock CLOV logo
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

#2408 Ranked by Market Cap
N/A Ranked by Dividends

CLOV Latest News

Sep 3, 2025
Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way
Aug 5, 2025
Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth
Aug 4, 2025
Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease
Jul 31, 2025
Clover Health Applauds White House and CMS鈥� Push to 鈥淭ear Down Digital Walls,鈥� Accelerating and Simplifying Access to Health Data for Patients and Their Clinicians
Jul 29, 2025
Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution

CLOV Latest SEC Filings

Aug 18, 2025
[Form 4] Clover Health Investments, Corp Insider Trading Activity
Aug 14, 2025
[Form 4] Clover Health Investments, Corp Insider Trading Activity
Aug 12, 2025
[Form 4] Clover Health Investments, Corp Insider Trading Activity
Aug 11, 2025
[8-K] Clover Health Investments, Corp Reports Material Event
Aug 8, 2025
[10-Q] Clover Health Investments, Corp Quarterly Earnings Report

CLOV Stock Data

1.38B
403.53M
3.88%
35.16%
8.04%
Healthcare Plans
Hospital & Medical Service Plans
United States
JERSEY CITY